Bringing in the Research Dollars! (BiRD)



Highlighting Pediatric Research Funding Opportunities

Brought to you by: The Emory+Children's Pediatric Research Center

Contact stacy.heilman@emory.edu with questions on the funding opportunities highlighted below or for general research grant application advice.

BiRD Highlights

- ❖ NIH Common Fund Initiatives invites investigators to develop bold and risky approaches in research; includes the <u>DP1 NIH Pioneer Award Program</u>, and the <u>Transformative R01 Research Award</u>, plus for early stage/new investigators, the <u>DP5 Early Independence Award</u> and the <u>DP2 NIH Director's New Innovator Award Program</u>
- ❖ Program Project Grant Potpourri! Featuring multiple P01 FOA's including offerings by NIGMS, NIDDK, NHLBI, NCI and a Novel NeuroAIDS opportunity. If you are interested in learning more about the P01 NIH grant mechanism, please contact stacy.heilman@emory.edu
- Cooperative Agreement opportunities for a <u>specialized center in rare</u> <u>diseases</u> and for a <u>clinical trial planning grant for NIDDK multi-center trials</u>
- Specialized R01 opportunities for <u>Omic and symptom science</u>, <u>stem cell research related to developing or damaged tissues</u> and for <u>adapting adult biomarkers to the field of pediatrics</u>
- Program specific funds to develop a collaborative and interdisciplinary team to <u>address issues relevant to the mission of NIDDK</u> and to build an <u>education program to facilitate the conduct of Patient-Centered Outcomes</u> Research
- STTR and SBIR <u>funds to develop point-of-care technologies for heart, lung, blood and sleep disorders</u>

- ❖ To examine the <u>role of the environment on autoimmune disease</u> development
- * Research to improve <u>self-management and quality of life in children with</u> chronic illness
- Burroughs Wellcome funded program for <u>Medical Scientists</u> and for investigators focused on the pathogenesis of infectious disease
- Career Development opportunities for <u>pediatric oncology researchers</u>, for investigators <u>new to the field of HIV research</u> and for <u>innovative bioethics</u> research
- ❖ Pilot funding for <u>regenerative medicine research efforts</u> and for "Quick Wins" that are expected <u>to produce a rapid solution to address an unmet</u> clinical need
- ❖ Notices from NIH for the <u>Loan Repayment Program</u> and from Emory for <u>EndNote training</u>

Federal					
Program/Link	NIH Pioneer Award Program (DP1)				
	http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-13-006.html				
Purpose	The NIH Pioneer Award initiative complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges that have the potential to produce an unusually high impact on a broad area of biomedical or behavioral research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere.				
Funds Available	Up to \$500,000 Direct Costs each year for five years				
Deadline	October 18, 2013, October 10, 2014, and October 9, 2015				
Remarks	 Applications with multiple PD(s)/PI(s) will not be accepted The NIH intends to commit approximately \$5,000,000 for approximately 7 awards in each fiscal year 2014 - 2016 				
Program/Link	NIH Transformative Research Awards (R01) http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-13-008.html				
Purpose	The NIH Transformative Research Awards complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad				

area of biomedical or behavioral research.

Funds Available

Application budgets are not limited but need to reflect the actual needs of the proposed research. Maximum project period is five years.

Deadline

October 4, 2013

LOI due Sept 4, 2013

Remarks

- Projects in any area of NIH interest, including basic, clinical, translational and behavioral studies, are encouraged and will be considered responsive to this FOA
- ➤ Applicants proposing clinical research should contact Program staff at the appropriate NIH Institute or Center (IC) to ensure that their applications conform to IC-specific policies for clinical research

Program/Link

Support of NIGMS Program Project Grants (P01)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-280.html

Purpose

Encourages innovative, interactive Program Project grant applications from institutions/organizations that propose to conduct research which aims to solve a significant biological problem, important for the mission of NIGMS, through a collaborative approach involving outstanding scientists. NIGMS supports research in the broad areas of Cell Biology and Biophysics; Genetics and Developmental Biology; Pharmacology, Physiology, and Biological Chemistry; and Bioinformatics and Computational Biology. The Program Project grant is designed to support research in which the funding of several interdependent projects offers significant scientific advantages over support of these same projects as individual regular research grants. The individual projects must be clearly interrelated and synergistic so that the research ideas, efforts, and outcomes of the program as a whole will offer a distinct advantage over pursuing the individual projects separately; the exact synergy and added value to be obtained by using the Program Project grant approach must be clearly articulated in the application.

Funds Available

An upper limit of \$6,500,000 direct costs for the entire five year project period may be requested.

Deadline

Standard NIH Deadlines*

Remarks

- Program project grants are investigator initiated, but this call is restricted to areas of special interest to the individual divisions within NIGMS (see http://www.nigms.nih.gov/About/overview for scientific areas of interests)
- Current NIH policy permits a component research project of a multi-project grant application to be concurrently submitted as a traditional individual research project (R01) application. If, following review, both the multi-project application and the R01 application are found to be in the fundable range, the investigator must relinquish the R01 and will not have the option to withdraw from the multi-project grant
- If you are interested in learning more about the PO1 NIH grant mechanism, please contact stacy.heilman@emory.edu

Program/Link

NIDDK Program Projects (P01)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-266.html

Purpose

Invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, endocrine and metabolic diseases, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research.

Funds Available

Applications cannot request more than \$6.25 million in direct costs over 5 years.

Deadline

Standard NIH Deadlines*

Remarks

- > The P01 program project award supports research that has multiple distinct but synergistic projects built around a unifying central theme relevant to the **NIDDK**
- Potential applicants are strongly encouraged to contact NIDDK while they are still in the process of developing conceptual plans for an application and at least 6 months before the due date to discuss a potential application. The discussion could include the choice of activity code, relevance of the topic to the NIDDK mission and the scope and approach of the project
- A description of NIDDK scientific program areas can be found at http://www2.niddk.nih.gov/Funding/default.htm
- ➤ If you are interested in learning more about the PO1 NIH grant mechanism, please contact stacy.heilman@emory.edu

Program/Link

NHLBI Program Project Applications (P01)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-316.html

Purpose

This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Each PO1 application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. In addition to individual research projects, applicants may propose one or more shared resource core(s) as necessary to facilitate the proposed research projects.

Funds Available

Application budgets are not limited but it is recommended that applicants not request a budget exceeding \$1,515,000 in direct costs per year. The maximum program period is 5 years.

Deadline

Standard NIH Deadlines*

- The Institute is particularly interested in encouraging new scientific directions in Program Project Grants. The P01 activity code is viewed as an opportunity to attract scientists who have not traditionally been supported by the NHLBI. However, all projects must be interrelated and have objectives that address a central theme within the scientific mandate of the Institute
- Investigators are encouraged to visit the NHLBI website for additional information about the research mission and high-priority research areas of the NHLBI (http://www.nhlbi.nih.gov/about/strategicplan/index.htm)

Remarks

- > Applicants should discuss equipment requests with NHLBI staff early in the planning phase and must receive permission from the Institute to include equipment costs in their budget request
- If you are interested in learning more about the PO1 NIH grant mechanism, please contact stacy.heilman@emory.edu

National Cancer Institute Program Project Applications (P01)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-321.html

Purpose

The National Cancer Institute (NCI) invites applications for investigator-initiated program project (P01) grants. Proposed program projects may address any of the broad areas of cancer research, including (but not limited to cancer biology, cancer treatment, cancer diagnosis, cancer prevention, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each Program Project application must consist of at least three projects. The projects must share a common central theme, focus, and/or overall objective.

Funds Available

Application budgets are not limited, but need to reflect the actual needs of the proposed program project. Maximum project period is 5 years.

Deadline

Standard NIH Deadlines*

Remarks

- In addition to individual research projects, applicants may propose one or more Shared Resource Cores if needed for the proposed research. Both administrative and research support cores are allowed
- If you are interested in learning more about the PO1 NIH grant mechanism, please contact stacy.heilman@emory.edu

Program/Link

Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01) http://grants.nih.gov/grants/guide/pa-files/PAR-13-267.html

Purpose

To develop innovative programs to advance therapeutics for NeuroAIDS. This Funding Opportunity Announcement (FOA) will support research programs that will advance central nervous system (CNS)-focused therapeutic approaches to: a) address HIV-associated neurocognitive disorders in HIV-infected individuals on highly active anti-retroviral therapy (HAART), b) eradicate persistent HIV-1 from the CNS during chronic infection, c) prevent establishment of HIV-1 in the brain during early infection, and d) assess the potential for CNS toxicity using HAART or candidate drugs that are currently in clinical studies to eradicate HIV-1. Studies to create or adapt existing animal models of HIV-1 infection in the CNS may be proposed to enable assessment of novel HIV CNS-focused therapeutic candidates. Multi-disciplinary, multi-project programs that are focused on improving neurocognition in HIV-infected persons are encouraged. A well defined, synergistic and milestone-driven plan for discovery, preclinical, and/or early clinical hypothesis-driven research should be presented. Public-private partnerships are encouraged but not required.

Funds Available

For applications proposing basic research exclusively throughout the 5 year term, up to \$675,000 direct costs may be requested yearly. Applications proposing the use of large animals (e.g., non-human primates) may request up to \$800,000 direct costs in any year(s) that such large animals will be needed and, for

applications proposing pilot clinical studies, the budget may include up to \$950,000 direct costs in any year(s) in which clinical studies are being conducted.

Deadline

January 7, 2014, January 7, 2015, January 7, 2016

Remarks

- ➢ Given the difficulty of pursuing HIV-1 in the CNS of humans, this funding announcement also encourages applications that focus on adapting or refining existing animal models that will then be used to test CNS-focused therapeutic strategies. Thus, animal models of viral infection of the CNS will be used for the two therapeutic goals of this initiative: treatment and prevention of HAND and HIV-1 eradication from the CNS
- This FOA provides the option to form partnerships between academia and the private sector to facilitate the translation of innovative therapeutic discoveries to clinical evaluation in humans
- If you are interested in learning more about the PO1 NIH grant mechanism, please contact stacy.heilman@emory.edu

Program/Link

NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-268.html

Purpose

NIDDK supports investigator-initiated, multi-center (three or more sites) clinical studies exclusively through a two-part process that includes an implementation planning cooperative agreement (U34). The U34 is designed to: (1) permit early peer review of the rationale for the proposed clinical study; (2) permit assessment of the design and protocol of the proposed study; (3) provide support for the development of documents needed for the conduct of the study, including a manual of operations; and (4) support the development of other essential elements required for the conduct of a clinical study.

Funds Available

Budgets for direct costs of up to \$225,000 per year for a maximum of 2 years are allowed. The funds requested are expected to vary based on the number of clinical sites involved in the study and the complexity of the study.

Deadline

April 15, 2014; Feb 19, 2015; June 17, 2015; April 18, 2016; Feb 14, 2017

Remarks

- ➤ Consultation with NIDDK staff is strongly encouraged prior to the submission of the U34 application
- Completion of the required products of a U34 is a prerequisite for submission of a multi-center clinical study cooperative agreement (U01) application, which will support the actual conduct of the study

Program/Link

Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54)

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-13-002.html

Purpose

To facilitate clinical research in rare diseases through support for 1) collaborative clinical research in rare diseases, including longitudinal studies of individuals with rare diseases, clinical studies and/or clinical trials; 2) training of clinical investigators in rare diseases research; 3) pilot/demonstration (proof of concepts) clinical research projects; and 4) access to information related to rare diseases for basic and clinical researchers, academic and practicing physicians,

patients, and the lay public.

Funds Available

Application budgets are limited to \$1.25 million total cost per year, for a total of 5 years of support

Deadline

November 7, 2013

Remarks

- ➤ Each RDCRC will perform collaborative multi-site clinical research in rare diseases, train new investigators in rare diseases research, and provide content for an internet resource site on rare diseases
- ➤ Each RDCRC will consist of a consortium of clinical investigators, institutions, and relevant organizations, including patient advocacy group organizations and will focus on at least three related rare diseases, disorders or syndromes
- Check RFA for a list of participating institutes/centers and example research areas of interest for each
- We would like to help organize a pediatric focused application in response to this RFA. If you have an idea for submission, please contact stacy.heilman@emory.edu by Sept 3, 2013

Program/Link

Synergizing Omic and Symptom Science (R01)

http://grants.nih.gov/grants/guide/pa-files/PA-13-264.html

Purpose

To promote integration of diverse information from molecular and biological processes with patient-reported outcomes (i.e. symptoms, functional status, health-related quality of life).

Examples of research in this area may include but are not limited to the following:

- Identify biomarkers and other classifiers to assess individual susceptibilities to variations in patient-reported outcomes
- Use novel methods to include modeling approaches and use of emerging technologies to measure and predict associations among omic variants and patient-reported outcomes
- Design and test tailored interventions to improve treatment outcomes

Funds Available

Application budgets are not limited, but need to reflect the actual needs of the proposed project. Maximum project period is 5 years.

Deadline

Standard NIH Deadlines*

Remarks

National Institute of Nursing Research (NINR) is the sole participating organization sponsoring this FOA

Program/Link

Differentiation and Integration of Stem Cells (Embryonic and Induced-Pluripotent) Into Developing or Damaged Tissues (R01)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-094.html

Purpose

To promote *in vivo* studies of stem cells in animal models and in humans (if applicable) to better understand how stem cells function within developing or damaged tissues. The areas of emphasis would include systematically profiling and cataloging changes at genetic and epigenetic levels that take place in stem cells and their microenvironment. The purpose is to gain in-depth knowledge of the mechanisms involved in: progressive differentiation of Embryonic Stem Cells

(ESCs) into embryonic lineages, progenitor cells and specialized cell types; adult stem cells/progenitor cells during tissue regeneration and wound healing; and Induced Pluripotent Stem Cells (iPSCs) at the site of injury during stem cell therapy. Understanding the basic mechanisms and application of knowledge-based approaches would allow researchers to generate iPSCs that are more closely related to the ESCs at both genetic and epigenetic levels. Furthermore, it is expected that replicating developmental mechanisms would ameliorate the safety concerns associated with incomplete differentiation and improper integration of cells in damaged or diseased tissues during stem cell therapy.

Per <u>NOT-HD-13-010</u>, research projects are restricted to the following developmental and pathological conditions:

- Research on developmental disorders, including structural birth defects and intellectual disabilities
- Research on the pathophysiology and management of chronically injured nervous and musculoskeletal systems (including stroke, traumatic brain injury, spinal cord injury, and orthopedic conditions); repair and recovery of motor and cognitive function; functional plasticity, adaptation, and windows of opportunity for rehabilitative interventions
- Research on reproductive pathophysiology, development of more effective strategies for management, and prevention of conditions that compromise fertility.

Funds Available

Budget may not exceed \$500K direct costs per year. Maximum project period is 5 years.

Deadline

Standard NIH Deadlines*

Remarks

- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the sole participating organization sponsoring this announcement
- Companion FOA is the R21 Exploratory/Developmental Grant http://grants.nih.gov/grants/guide/PA-files/PAR-13-095.html

Program/Link

Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care STTR (R41/R42)

http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-017.html

Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support research using advanced technologies to develop novel point-of-care (POC) devices and implement existing technologies in clinical settings with a goal to guide diagnostic and therapeutic efforts for the heart, lung, blood (HLB) and sleep disorders.

Funds Available

Budgets up to \$225,000 total costs for Phase I and up to \$1,500,000 total costs for Phase II may be requested. Award periods normally may not exceed 1 year for Phase I and 2 years for Phase II.

Deadline

October 15, 2013; October 15, 2014; October 15, 2015, October 15, 2016

Remarks

> Special note: Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity, but...

- ➤ In Phase I and Phase II STTR's, at least 40% of the research or analytical effort must be performed by the small business concern and at least 30% of the research or analytical effort must be performed by a, <u>partnering research</u> institution
- ➤ The PD(s)/PI(s) may be employed with the SBC or the single, partnering nonprofit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC
- Companion SBIR RFA http://grants1.nih.gov/grants/guide/rfa-files/RFA-HL-14-011.html

The Role of Environmental Exposures in the Development of Autoimmune Disease (R21)

http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-13-011.html

Purpose

Encourages exploratory research applications aimed at investigating the role environmental exposures play in the development and/or the exacerbation of autoimmune disease. Applicants may propose to use in vitro studies or animal models to explore possible mechanisms in which environmental exposures associated with human autoimmune endpoints are involved in the induction of an autoimmune response or an autoimmune disease. Of particular interest are projects that will identify and characterize critical windows of exposure susceptibility, projects that explore mechanisms responsible for gender differences in response and development of autoimmune disease, and studies that can produce potential biomarkers for use in subsequent human surveillance studies.

Funds Available

The combined budget for direct costs for the 2-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. Applicants may request direct costs in \$25,000 modules, up to the total direct costs limitation of \$275,000 for the combined two-year award period.

Deadline

November 15, 2013

Remarks

- ➤ Applicants must propose research programs where published data in human cohorts has demonstrated a potential role and/or mechanism by which the environmental exposure of interest can influence the development and/or the exacerbation of autoimmune disease
- ➤ The sole participating organization is National Institute of Environmental Health Sciences (NIEHS)

Program/Link

Biomarkers: Bridging Pediatric and Adult Therapeutics (R01)

http://grants.nih.gov/grants/guide/pa-files/PAR-13-296.html

Purpose

Encouraging grant applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to pediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy.

Projects supported by this FOA will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have pediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies is

not part of this FOA. Also excluded are biomarkers for diseases that are unique to children and have no adult correlates.

Funds Available

Application budgets are not limited, but need to reflect the actual needs of the proposed project. Maximum project period is 5 years.

Deadline

Standard NIH Deadlines*

Remarks

- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the sole participating organization
- This FOA is expected to foster collaboration between pediatric and adult medicine investigators in related disciplines
- Companion FOA's
 - R03 Small Grant Program <u>http://grants.nih.gov/grants/guide/pa-files/PAR-13-299.html</u>
 - R21 Exploratory/Developmental Grant http://grants.nih.gov/grants/guide/pa-files/PAR-13-295.html

Program/Link

Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24) http://grants.nih.gov/grants/guide/pa-files/PAR-13-305.html

Purpose

Encouraging applications that assemble an interdisciplinary, collaborative team of creative, independent, and funded investigators to address a complex and important problem relevant to the mission of NIDDK. The team should be able to provide an integrative plan of working together to effectively address the complex challenge at hand. The team science approach encouraged by this FOA could be used to generate a research resource, which may include discovery-based or hypothesis-generative approaches, to advance the relevant area of biomedical research.

Applications to this FOA should have the following characteristics:

- The formation of an interdisciplinary team that will develop a synergistic approach to investigate a single critically important research question or to generate a research resource for the scientific community.
- The question addressed should represent a major gap in our knowledge and thus have the potential to be paradigm-shifting.
- Team members should be established, independent and creative investigators with active research support.
- Team members, who can be at the same or different institutions, should be a highly collaborative and interactive group.

Funds Available

Application budgets are not limited, but need to reflect the actual needs of the proposed project. Maximum project period is 5 years.

Deadline

November 15, 2013; November 13, 2014; and November 17; 2015

Remarks

- ➤ The R24 code is designed to support research projects that will enhance the capability of resources to serve biomedical research. In this FOA, the R24 is being used to provide a mechanism by which interdisciplinary expertise is brought together to focus on a single complex problem in biomedical research relevant to the mission of NIDDK.
- Consultation with NIDDK staff at least 3 months (and preferably 6 months)

- prior to the application due date is strongly encouraged
- > See RFA for examples from successfully funded R24 applications
- There is a limited pool of funds for these and similar large grants making them highly competitive; other collaborative research opportunities should be considered
- This FOA is not intended to support:
 - Traditional investigator-initiated and highly focused studies (best supported by the R01 or P01 mechanism)
 - o Research that is the logical extension of ongoing work
 - Core (or related) services to supplement the budgets of existing R01type efforts
 - Groups of investigators at the same institution who would normally interact and collaborate in the absence of a collaborative grant

Researcher Training and Workforce Development in Methods and Standards for Conducting Patient-Centered Outcomes Research Studies (R25) http://grants.nih.gov/grants/guide/rfa-files/RFA-HS-14-004.html

Purpose

Inviting applications for grants to develop, implement, and evaluate an education program for researchers on methodologies and methodological standards used to conduct comparative clinical effectiveness and/or patient-centered outcomes research (CER/PCOR). The purpose of this initiative is to build capacity in the national scientific workforce to conduct high quality CER/PCOR studies. Applicants will develop innovative programs that accommodate the educational needs of a respective professional field, employment setting, and/or researcher community. An education program must have multiple components and include basic, advanced, and experiential training opportunities. Programs may focus on the design and analysis of systematic reviews, technology assessments, observational studies, registries, clinical trials, and/or other approaches to CER/PCOR. Research methods guides produced by AHRQ and methodology standards adopted by the Patient-Centered Outcomes Research Institute are among the content materials that may be used to develop education program components.

Funds Available

Application budgets are limited to total costs (including direct and indirect costs) of \$500,000 in any given year. Because the nature and scope of the proposed research education activities will vary from application to application, it is anticipated that the size and duration of the award will also vary. Maximum award period is 5 years.

Deadline

September 27, 2013

Remarks

- The R25 mechanism provides support to develop and/or implement a program as it relates to a category in one or more of the areas of education, information, training, technical assistance, coordination, or evaluation
- Answers to FAQ's can be found at http://www.ahrq.gov/funding/fund-opps/rfahs14004faq.html

Program/Link

Chronic Illness Self-Management in Children and Adolescents (R01)

http://grants1.nih.gov/grants/guide/pa-files/PA-11-070.html

Purpose

The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute of Nursing Research (NINR), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Heart, Lung, and Blood Institute (NHLBI) is to encourage research to improve self-management and quality of life in children and adolescents with chronic illnesses. Children diagnosed with a chronic illness and their families have a life-long responsibility for self-management, to maintain and promote health and prevent complications. Biobehavioral studies of children in the context of family and family-community dynamics are encouraged. Research related to biological/technological factors, as well as, sociocultural, environmental, and behavioral mechanisms that contribute to successful and ongoing selfmanagement of chronic illnesses in children is also encouraged. This FOA is restricted to studies of chronic illnesses in children and adolescents ages 8 to 21 grouped by developmental stages according to the discretion of the investigator.

Funds Available

Application budgets are not limited, but need to reflect actual needs of the proposed project. Maximum project period is 5 years.

Deadline

Standard NIH Deadlines*

(**special note:** This PA expires on Jan 8, 2014; if it is not renewed, the only deadline that remains is Oct 5, 2013)

Remarks

- Studies of chronic mental illness or serious cognitive disability are beyond the scope of this FOA
- Companion FOA's
 - R03 Small Grant Program
 http://grants1.nih.gov/grants/guide/pa-files/PA-11-071.html
 - R21 Exploratory/Developmental Grant http://grants1.nih.gov/grants/guide/pa-files/PA-11-072.html

Foundation

Program/Link

Burroughs Wellcome Fund Infectious Disease - Investigators in the Pathogenesis of Infectious Disease http://www.bwfund.org/grant-programs/infectious-diseases

Purpose

The Investigators in the Pathogenesis of Infectious Disease program provides opportunities for assistant professors to bring multidisciplinary approaches to the study of human infectious diseases. The awards are intended to give recipients the freedom and flexibility to pursue high-risk projects and new avenues of inquiry. Work supported will have the potential to significantly advance the understanding of how microbes and the human system interact, especially in the context of infection. Biochemical, pharmacological, molecular, genetic, immunologic, and other approaches are all appropriate for support by the program. Areas of particular interest include:

- Cell/Pathogen interactions—studies of host responses at the cell surface, cell signaling in response to infection, microbial persistence in host cells, and other work.
- Host/Pathogen interactions—studies of how host genetics influences

resistance and susceptibility to infection, innate and adaptive immune responses to microbes, pathogen modulation of the immune system, and other work.

 Novel routes to disease causation—studies of the role of infectious agents in the etiology of chronic, autoimmune, and immunologic diseases, and other work.

Deadline

Internal Deadline: October 1, 2013

(If invited by Emory to submit, Agency Deadline is Nov 1, 2013 by 4pm EST)

Remarks

- Emory may make TWO nominations. Interested applicants should submit a two-page abstract (abstract should include along with your name and contact info, 1-specific aims and hypotheses, 2-background & significance, 3-preliminary data when available and 4-outline of research design & methods) plus a NIH biographical sketch to Trish Haugaard patricia.haugaard@emory.edu
- ➤ ELIGIBILITY: Candidates must have an established record of independent research and hold a tenure-track position as an assistant professor or equivalent (at the time of application). Researchers recently appointed to a faculty position may not have a demonstrated track record sufficient to compete successfully for this award. Exceedingly few newly appointed assistant professors have sufficient independence. Most successful applicants are at or well past their third complete year as an Assistant Professor.
- After reviewing the requirements, take the <u>Eligibility Quiz</u> to determine whether or not you are eligible to apply for this award. If you meet the eligibility requirements, the system will allow you to begin an application.

Research Training & Career Development

Program/Link

Burroughs Wellcome Fund – Career Awards for Medical Scientists (CAMS) http://www.bwfund.org/grant-programs/biomedical-sciences/career-awards-

medical-scientists

Purpose

To bridge advanced postdoctoral/fellowship training and the early years of faculty. Proposals must be in the area of basic biomedical, disease-oriented, or translational research. Proposals in health services research or involving large-scale clinical trials are ineligible.

Funds Available

\$700,000 over five years

Deadline

Internal Deadline: September 3, 2013

(If invited by Emory to submit, Agency Deadline is Oct 1, 2013 by 4pm EST)

Remarks

- Interested applicants should submit a two-page abstract (abstract should include: your name, contact info, specific aims and hypotheses, background & significance, preliminary data where available and outline of research design & methods) and a NIH biographical sketch to Trish Haugaard patricia.haugaard@emory.edu OR Kelly Simily Shaw ksimily@emory.edu
- > The ideal candidate will be two years away from becoming an independent investigator, have at least two years or more of postdoctoral research

- experience, and have a significant publication record
- There are multiple eligibility requirements; An eligibility quiz has been created to assist in determining eligibility: http://www.bwfund.org/grant-programs/biomedical-sciences/career-awards-medical-scientists/eligibility
- Emory University may nominate up to five candidates

The Greenwall Foundation Faculty Scholars Program in Bioethics

http://greenwall.org/how-to-apply.php

Purpose

A career development award to enable junior faculty members to carry out innovative bioethics research. This program supports scholars whose work will have an impact on public policy, biomedical research, or clinical practice. Faculty Scholars will be selected on the basis of their achievements, the strength of their research project, their commitment to the field of bioethics, and support from their home institution. While the amount and quality of an applicant's research in bioethics will count favorably towards his/her application, outstanding candidates with less direct experience in bioethics will also be considered.

Within this group, priority will be given to applicants whose research addresses innovative and emerging topics. Lower priority will be given to applicants who are primarily carrying out institutional change, educational reform, or theoretical bioethics research.

Funds Available

The award supports 50% of a Scholar's salary plus benefits for three years, up to the NIH cap, with 10% institutional costs for the salary and benefits. In addition, we provide \$5000 each year for limited project support and travel.

Deadline

Internal Deadline: Sept 10, 2013 (Agency Deadline for those invited to submit is Nov 1, 2013)

Remarks

➤ Interested applicants must submit an abstract of their proposed projects (not to exceed 2 pages) and an NIH-style biosketch to Holly Sommers via e-mail (<a href="https://nscene.org/nsc

Program/Link

NIH Director's Early Independence Awards (DP5)

http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-13-009.html

Purpose

Supports cross-cutting programs that are expected to have exceptionally high impact. Applications should propose bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. Supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

Funds Available

Up to \$250,000 direct costs per year for five years

Deadline

January 31, 2014*

^{*}Each institution may submit a maximum of two applications so an internal

competition processed will be announced. Contact stacy.heilman@emory.edu if you wish to compete in the Emory based internal selection process.

Remarks

- At the time of application, the Early Independence Award candidate must be within twelve months before or after the completion of their PhD (or equivalent) or for clinicians within twelve months before or after the completion of their medical residency (or equivalent) training
- > Approximately 10 awards are anticipated to be made in FY 2014

Program/Link

NIH Director's New Innovator Award Program (DP2)

http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-13-007.html

Purpose

Supports a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The New Innovator Award initiative complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators.

Funds Available

Up to \$300,000 direct costs per year for five years

Deadline

October 25, 2013, October, 17, 2014, and October 16, 2015

Remarks

- Applicants must meet the definition of an Early Stage Investigator (ESI). An ESI is a new investigator (defined as a PD/PI who has not completed successfully for a significant NIH independent research award) who is within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent)
- Awardees are required to commit at least 25% of their research effort each year to activities supported by the New Innovator Award
- ➤ Applicants may submit or have an R01 (or other equivalent) grant application pending concurrently with their New Innovator Award application. However, if that pending grant is awarded in the fiscal year of the competition (fiscal years end September 30) with a start date of September 30 or earlier in that fiscal year, then the applicant is no longer eligible to receive the New Innovator Award
- For more details regarding eligibility requirements, see FAQs on the New Innovator website at http://commonfund.nih.gov/newinnovator/
- ➤ NIH intends to commit approximately \$80 million for approximately 33 awards in each of the fiscal years 2014 2016

Program/Link

Alex's Lemonade Stand 'A' Awards

http://www.alexslemonade.org/files/grants a award.pdf

Purpose

The 'A'Awardis a three-year grant designed for the early career scientist who wants to establish their career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of outstanding mentorship and a future commitment to pediatric cancer investigation are critical components of a successful application.

Funds Available

\$125,000 per year for three years.

Deadline 9/16/13

Remarks Eligibility (see RFA for additional requirements & restrictions):

- o MD applicants must be no more than 6 years from finishing fellowship at the time the award would start
- o PhD applicants must be no more than 6 years since being awarded their degree
- Requires 75% applicant effort
- Institutional commitment to the applicant is expected

Program/Link Creative and Novel Ideas in HIV Research (CNIHR) grant program http://www.cnihr.org

Purpose

The Creative and Novel Ideas in HIV Research (CNIHR) grant program welcomes innovative proposals from early-stage scientists without prior experience in HIV research to answer essential questions in HIV research, including emerging issues of long term survival with HIV infection, prevention of HIV transmission, and research toward a cure.

Funds Available Awards are funded for 1-2 years, up to \$150,000 (direct costs) per year.

Deadline October 16, 2013 for phase 1 concept proposals (The deadline for those who are invited to submit full proposals will be Feb 10,

2014)

Eligibility Criteria: Remarks

- Early-stage investigators who have completed their first terminal research degree or medical residency after October 16, 2003 and who have a faculty or equivalent position at an academic institution or a comparable position at a not for profit research organization or institution at the time of full proposal submission are eligible
- o Applicants must have not yet been engaged in HIV research. Any previous grant, contract, sub-award, or publication in HIV or SIV research is disqualifying

Pilot/Seed Fund Opportunities

Children's/GA Tech Quick Wins Program/Link https://pediatriconnect.gtri.gatech.edu/grants

Purpose Do you have a brilliant idea for a system, device or program that would make life

better 'For the Kids?' Quick Wins is a program that provides funds to facilitate development of solutions to address unmet clinical and business needs at Children's Healthcare of Atlanta. Proposed projects should be designed to deliver a workable solution into the hands of a clinician or clinical team within 18 months from the receipt of funds and project start. The proposing team must include individuals from both Children's Healthcare of Atlanta and Georgia Tech.

Funds Available Varies (~\$50k - \$150K)

Deadline Rolling deadline. Project proposals are reviewed monthly.

Remarks For more information, please contact Leanne.West@gtri.gatech.edu or

Brittiany.hailey@gtri.gatech.edu

Program/Link	Regenerative, Engineering and Medicine Seed Grants			
	http://regenerativeengineeringandmedicine.com/rem-seed-grants			
Purpose	This funding mechanism is intended to stimulate new, collaborative research in regenerative medicine and supports both basic science and translational research. The funds are intended to promote the acquisition of extramural funding and the application must include a description of the long term funding strategy. Two proposal types are invited:			
	Strategic Priority Grants – This funding mechanism is intended for developed projects that are supported by preliminary data. These proposals should be at an advanced preclinical or early clinical stage with a viable clinical target potential.			
	Innovative Research Grants – This funding mechanism is intended to fund projects at earlier stages of development. Proposals that are more speculative in nature that fall into the "high risk, high yield" category may be more appropriate for this mechanism.			
Funds Available	\$75,000 for one year			
Deadline	Sept 1, 2013			
Remarks	Proposals should include a team of investigators (minimum of two) and must have an equal partnership of faculty from Georgia Tech and Emory and resources split between the universities as equally as possible			
	Proposals from investigators who are new to the regenerative medicine field,			

those addressing new questions or taking new approaches are encouraged No investigator may receive regenerative medicine seed grant funding for

Notices/Other:

Extramural Loan Repayment Program for Pediatric Research (LRP-PR)

NOT-OD-13-083

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-083.html

http://www.lrp.nih.gov/about the programs/pediatric.aspx

The objective of the <u>LRP-PR</u> program is to recruit and retain highly qualified health professionals as pediatric investigators. (NIH defines Pediatric Research as "research that is directly related to diseases, disorders, and other conditions in children.")

more than 3 years out of any 5 year period

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for at least two years, and who agree to engage in such research for at least 20 hours per week based on a 40-hour work week, to apply for participation in the extramural LRP. Extramural LRPs provide for the repayment of educational loan debt of up to \$35,000 annually for qualified health professionals performing research within the mission of NIH at domestic, non-profit, or government entities. **LRP applications will be accepted**

annually from September 1 through November 15, 8:00 p.m. EST. Applications must be submitted electronically using the NIH Loan Repayment Program Website, www.lrp.nih.gov.

Emory Specific Instructions:

As part of the application process, every applicant is required to identify an "Institutional Contact" who will provide official verification to NIH on Emory's behalf of the applicant's base salary and availability of time and resources to conduct the proposed research.

To facilitate this process, when completing their LRP applications, all School of Medicine applicants should identify Joshua Barwick as their Institutional Contact with the following information:

Joshua Barwick, J.D.

Associate Dean for Administration Email: joshua.barwick@emory.edu

Phone: 404-712-9793

Class: Create Bibliographies with EndNote

http://health.library.emory.edu/what-we-do/workshops-and-training-sessions#/?i=1

When: Upcoming Sessions include Aug 27th, Sept 5th, Sept 17th *Check website url for additional dates in October and beyond*

Where: WHSC Library E-Classroom Topics covered: Core EndNote functions. Audience: Open to all Emory audiences

After this session you will know how to:

- create an EndNote Library
- manually enter references into the library
- import references from databases
- generate bibliographies.

*NIH STANDARD DUE DATES CITED ABOVE

	Cycle I	Cycle II	Cycle III
Mechanism(s)	Due Date	Due Date	Due Date
P Series			
ALL – new, renewal,	25-Jan	25-May	25-Sept
resubmission, revision		·	
R01			
NEW			
	5-Feb	5-Jun	5-Oct
renewal, resubmission,			
revision	5-Mar	5-Jul	5-Nov

G12, M01, R10/U10, R24, R24/U24, S06, U19, U45, U54, U56 All - new, renewal, resubmission, revision	25-Jan	25-May	25-Sept
R41, R42, R43, R44, U43, U44, All - new, renewal, resubmission, revision	5-April	5-Aug	5-Dec
R03, R21, R34 NEW renewal, resubmission,	16-Feb	16-Jun	16-Oct
revision K series	16-Mar	16-Jul	16-Nov
NEW NEW	12-Feb	12-Jun	12-Oct
renewal, resubmission, revision	12-Mar	12-Jul	12-Nov
All AIDS and AIDS-Related Applications (for mechanisms cited above)			
All - new, renewal, resubmission, revision	7-May	7-Sept	7-Jan

For the full schedule of NIH standard due dates, see http://grants1.nih.gov/grants/funding/submissionschedule.htm



This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community. It is compiled by the Emory+Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listsery, please e-mail stacy.heilman@emory.edu to make the request. Please also contact Stacy if you are interested in applying for any pediatric focused research funding opportunities and/or if you are working towards building collaborative efforts and programs towards applying for pediatric research funding in the future.